Ecarin Clotting Time but not aPTT Correlates with PEG-Hirudin Plasma Activity
- 52 Downloads
Background: Novel antithrombotic agents such as hirudin have shown promise in the therapy of acute coronary syndromes. PEG-hirudin (polyethyleneglycol conjugated hirudin) has been developed to provide a longer plasma half-life and more stable antithrombotic plasma levels. Privious trials indicated a narrow therapeutic window for hirudin and a number of aPTT (activated partial thromboplastin time)-monitored trials investigating hirudin in acute coronary syndromes had to be stopped because of intracranial bleeding complications.
Objectives: The present study evaluates the ecarin clotting time (ECT), a parameter based on the conversion of prothrombin by the snake venom enzyme ecarin, for the monitoring of PEG-hirudin therapy.
Methods: Plasma from either healthy volunteers (n=20) or from patients (n=10) suffering from unstable angina pectoris (UAP) was spiked with increasing PEG-hirudin concentrations. In a prospective randomized clinical trial patients with UAP were treated with intravenous PEG-hirudin or heparin over 72 hours. Patients were randomized to the following treatment groups: (1) heparin control group, n=15; (2) PEG-hirudin low dose (0.1[emsp4 ]mg/kg bolus, 0.01[emsp4 ]mg/kg/h infusion), n=19; (3) intermediate dose (0.15[emsp4 ]mg/kg and 0.015[emsp4 ]mg/kg/h), n=17; 4) high-dose (0.2[emsp4 ]mg/kg and 0.02[emsp4 ]mg/kg/h), n=16. Spiked plasma samples and plasma from UAP patients treated with i.v. PEG-hirudin were analyzed for aPTT, ECT, and PEG-hirudin levels.
Results: A linear correlation up to the highest therapeutic concentrations could be observed between PEG-hirudin plasma concentrations and the ECT. This was true for both plasma samples spiked with PEG-hirudin in vitro as well as for samples taken from patients treated with i.v. PEG-hirudin (correlation coefficient 0.9, respect.) In contrast the aPTT did not show a reliable linear correlation to PEG-hirudin concentrations.
Conclusion: Monitoring of PEG-hirudin therapy by ECT may help to avoid inadequate anticoagulation or overdosing. Thus, the safety and efficacy profile of PEG-hirudin therapy is likely to be enhanced by ECT monitoring.
Unable to display preview. Download preview PDF.
- 1.Weitz JI. Activation of blood coagulation by plaque rupture: Mechanisms and prevention. Am J Cardiol 1995;75:18B–22B.Google Scholar
- 2.Bossavy J, Sakariassen K, Rübsamen K, Thalamas C, Boneu B, Cadroy Y. Camparison of the antithrombotic effect of PEG–hirudin and heparin in a human ex vivo model of arterial thrombosis. Atheroscl Thromb Vasc Biol 1999;19:1348–1353.Google Scholar
- 3.Rübsamen K, Hornberger W. Prevention of early reocclusion after thrombolysis of copper coil–induced thrombi in the canine carotid artery: comparison of PEG–hirudin and unfractionated heparin. Thromb Haemost 1996;76(1):105–110.Google Scholar
- 4.Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Mueller–Peltzer H. Pharmacodynamic and safety results of PEG–hirudin in healthy volunteers. Thromb Haemost 1997;77(5):911–919.Google Scholar
- 5.Zeymer U, von Essen R, Tebbe U, et al. Recombinant hirudin and front–loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT–I (hirudin for the improvement of thrombolysis). Eur Heart J 1995;(Suppl D):22–27.Google Scholar
- 6.Cannon C, McCabe C, Henry T. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with t–PA and aspirin for acute myocardial infarction: Results of TIMI–V trial. J Am Coll Cardiol 1994;23:993–1003.Google Scholar
- 7.Lee L. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of TIMI–6 trial. J Am Coll Cardiol 1995;75:7–13.Google Scholar
- 8.Antman E. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994;90:1624–1630.Google Scholar
- 9.The global use of strategies to open occluded coronary arteries (GUSTO) IIa investigators. Randomization of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90: 1631–1637.Google Scholar
- 10.Neuhaus K, van Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r–hirudin for improvement of thromboiysis (HIT–III) study. Circulation 1994;90:1638–1642.Google Scholar
- 11.The GUSTO–IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775–782.Google Scholar
- 12.The OASIS investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study. Circulation 1997;96:769–777.Google Scholar
- 13.The OASIS investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischemia without ST elevation: a randomized trial. Lancet 1999;353:429–438.Google Scholar
- 14.Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996;22:197–202.Google Scholar
- 15.Spannagl M, Bichler J, Birg A, Lill H, Schramm W. Development of a chromogenic substrate assay for the determination of hirudin in plasma. Blood Coagul Fibrinolysis 1991;2:121–127.Google Scholar
- 16.Pötsch B, Hund S, Madlener K, Unkrig C, Müller–Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma–based ecarin clotting time assay. Thromb Res 1997;86:373–383.Google Scholar
- 17.Pötsch B, Madlener K, Seelig C, Riess C, Greinacher A, Müller–Berghaus G. Monitoring of r–hirudin anticoagulation during cardiopulmonary bypass–assessment of the whole blood ecarin clotting time. Thromb Haemost V;77:920–925.Google Scholar